Latest News & Updates of Loncom Pharma

Bestcomm won "Independent Innovation Enterprise" and "Top 50 R&D Company" at the 2025–2026 Industry Conference.

ICH E6(R3) Annex 2 provides GCP guidance for decentralised, pragmatic, and RWD‑enriched trials. It emphasises proportionality, QbD, patient engagement, and early regulator dialogue, reshaping clinical trial quality management for the digital era.

Bestcomm Pharmaceutical has been named among the 2026 Top 20 Chinese Pharmaceutical CRO Enterprises by the PDI Summit. The ranking evaluates revenue, R&D investment, headcount, brand awareness, and more. As a leading one‑stop R&D solution provider, Bestcomm is committed to accelerating innovative drug development and delivering high‑quality therapies to patients.

Loncom Pharmaceutical wrapped up its 2026 Safety Production Month with record participation, practical emergency drills, and a knowledge contest. A comprehensive hazard inspection per AQ3067-2026 was completed. The company reinforces that rigorous safety management is the bedrock of drug quality and patient trust across all operations.